Abstract
Background The COVID-19 pandemic goes along with increased mortality from acute respiratory disease, and measures to limit the spread of the infection go along with increased risk of vitamin D deficiency, especially among high risk groups. It has been suggested that vitamin D3 supplementation might help to reduce respiratory disease mortality.
Methods We assessed the prevalence of vitamin D insufficiency and deficiency, defined by 25(OH)D blood levels of 30-50 and <30 nmol/L, respectively, and their association with mortality from respiratory diseases during 15 years of follow-up in a cohort of 9,548 adults aged 50-75 years from Saarland, Germany.
Results Vitamin D insufficiency and deficiency were common (44% and 15%, respectively). Compared to sufficient vitamin D status, respiratory disease mortality was 2.1 (95%-CI 1.3-3.2)- and 3.0 (95%-CI 1.8-5.2)-fold increased, respectively. Although significant increases were seen in both women and men, they were much stronger among women, with 8.5 (95% CI 2.4-30.1) and 2.3 (95% CI 1.1-4.4)-fold increase of respiratory disease mortality in case of vitamin D deficiency among women and men, respectively (p-value for interaction =0.041). Overall, 41% (95% CI 20%-58%) of respiratory disease mortality was statistically attributable to vitamin D insufficiency or deficiency.
Conclusion Vitamin D insufficiency and deficiency are common and account for a large proportion of respiratory disease mortality in older adults, supporting suggestions that vitamin D3 supplementation might make a major contribution to limit the burden of the COVID-19 pandemic, particularly among women.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The ESTHER study was funded by grants from the Saarland state Ministry for Social Affairs, Health, Women and Family Affairs (Saarbruecken, Germany), the Baden-Wuerttemberg state Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany) and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ESTHER study was approved by the ethics committees of the University of Heidelberg and the state medical board of Saarland, Germany.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The ESTHER data cannot be made publicly available due to legal restrictions. However, data can be shared on the basis of research proposals that are in accordance with the study's aims.
